Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Hormone Receptor-Positive Breast Carcinoma”

90 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 90 results

Not applicableStudy completedNCT01385280
What this trial is testing

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Cancer+2 more
University of Arizona 13
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164976
What this trial is testing

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Nagoya City University 86
Early research (Phase 1)Study completedNCT00328120
What this trial is testing

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

Who this might be right for
Advanced Breast Cancer
AstraZeneca 20
Not applicableStudy completedNCT01617954
What this trial is testing

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of Breast
Agendia 820
Large-scale testing (Phase 3)Active Not RecruitingNCT01272037
What this trial is testing

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Who this might be right for
Breast Ductal Carcinoma In SituInvasive Breast CarcinomaMulticentric Breast Carcinoma+2 more
National Cancer Institute (NCI) 5,018
Not applicableStudy completedNCT05912933
What this trial is testing

Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Who this might be right for
Breast Cancer
Pfizer 733
Large-scale testing (Phase 3)Study completedNCT00256698
What this trial is testing

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

Who this might be right for
Breast Cancer
AstraZeneca 514
Testing effectiveness (Phase 2)Study completedNCT02387099
What this trial is testing

Dose EScalation Induction of EvERolimus

Who this might be right for
Breast CancerHormone Receptor Positive Tumor
GBG Forschungs GmbH 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT04692103
What this trial is testing

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Who this might be right for
Estrogen Receptor PositivePrimary or Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 2
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Large-scale testing (Phase 3)Looking for participantsNCT07190443
What this trial is testing

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

Who this might be right for
Breast CancerLocoregional RecurrenceAbemaciclib+1 more
Japanese Foundation for Cancer Research 290
Large-scale testing (Phase 3)Active Not RecruitingNCT03820830
What this trial is testing

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Who this might be right for
Breast Cancer Recurrent
ETOP IBCSG Partners Foundation 405
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Testing effectiveness (Phase 2)Study completedNCT00010010
What this trial is testing

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
NYU Langone Health
Large-scale testing (Phase 3)Looking for participantsNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 300
Testing effectiveness (Phase 2)WithdrawnNCT00217659
What this trial is testing

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06702618
What this trial is testing

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Early research (Phase 1)Study completedNCT02820961
What this trial is testing

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor Positive Breast Cancer
Syndax Pharmaceuticals 61
Testing effectiveness (Phase 2)Looking for participantsNCT06923527
What this trial is testing

Circulating Tumor DNA

Who this might be right for
ER+ Breast Cancer
Yale University 50
Testing effectiveness (Phase 2)Ended earlyNCT02273752
What this trial is testing

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerGastrinomaGlucagonoma+16 more
Emory University 2
Load More Results